<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>" Egyption
Informatics Journal</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <title-group>
        <article-title>ProgMod: An Analytical Model for Prognosis Prediction of AML Patients Using Survival Regression and Gene Expression Levels</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <string-name>Ahmad Al Sayyid</string-name>
          <email>aelsayyid94@gmail.com</email>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Sara Makki</string-name>
          <email>sara.makki@cognitus.fr</email>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Rafiqul Haque</string-name>
          <email>rafiqul.haque@intelligencia.fr</email>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Ali Jaber</string-name>
          <email>alijaber30@hotmail.com</email>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Yehia Taher</string-name>
          <email>yehia.taher@uvsq.fr</email>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <aff id="aff0">
          <label>0</label>
          <institution>Department of Computer</institution>
          ,
          <addr-line>Science</addr-line>
          ,
          <institution>Lebanses Univesity - Faculty of, Sciences</institution>
          ,
          <addr-line>Beirut</addr-line>
          ,
          <country country="LB">Lebanon</country>
        </aff>
        <aff id="aff1">
          <label>1</label>
          <institution>Department of Computer</institution>
          ,
          <addr-line>Science</addr-line>
          ,
          <institution>Lebanses Univesity - Faculty of, Sciences</institution>
          ,
          <addr-line>Beirut</addr-line>
          ,
          <country country="LB">Lebanon</country>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution>Department of Computer</institution>
          ,
          <addr-line>Science</addr-line>
          ,
          <institution>Universite de Versailles StQuentin-en-Yvelines</institution>
          ,
          <addr-line>Paris</addr-line>
          ,
          <country country="FR">France</country>
        </aff>
        <aff id="aff3">
          <label>3</label>
          <institution>Department of Technological, Development, Cognitus</institution>
          ,
          <addr-line>Paris</addr-line>
          ,
          <country country="FR">France</country>
        </aff>
        <aff id="aff4">
          <label>4</label>
          <institution>Department of Technological, Development, Intelligencia R &amp; D</institution>
          ,
          <addr-line>Paris</addr-line>
          ,
          <country country="FR">France</country>
        </aff>
      </contrib-group>
      <pub-date>
        <year>2017</year>
      </pub-date>
      <fpage>94</fpage>
      <lpage>99</lpage>
      <abstract>
        <p>- An accurate prediction of prognosis to the patient diagnosed with Acute Myeloid Leukemia (AML) is an enormously difficult task. Several solutions have been proposed for prognosis prediction however there is a scope to improve current solutions. In this paper we aim at developing a solution that estimates the survival time that is the Prognosis of patients diagnosed with AML. To that end, we used a machine learning model that is built on an algorithm called Survival Regression. The model consumes as input the Expression Levels of a small number of the genes of the patient.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec-1">
      <title>-</title>
      <p>Keywords - AML, Gene Expression Levels, Machine
Learning, Prognosis, Survival Regression</p>
    </sec>
    <sec id="sec-2">
      <title>I. INTRODUCTION</title>
      <p>
        Acute Myeloid Leukemia (AML) is a form of cancer that
is characterized by infiltration of the bone marrow, blood, and
other tissues by proliferative, clonal, abnormally
differentiated, and occasionally poorly differentiated cells of
the hematopoietic system. Although it was incurable 50 years
ago, AML is now cured in 35 to 40% of adult patients who are
60 years of age or younger and in 5 to 15% of patients who
are older than 60 years of age. The outcome in older patients
who are unable to receive intensive chemotherapy without
unacceptable side effects remains dismal, with a median
survival of only 5 to 10 months [
        <xref ref-type="bibr" rid="ref1">1</xref>
        ]. Producing an accurate
prognosis to the patient diagnosed with AML difficult due to
its enormous molecular heterogeneity, which means that the
disease manifests itself with wide diversity on the molecular
level. However, now with the medical insight provided by the
genetic profile of the patient, the possibility of acquiring a
prognosis by studying his genes is promising, especially with
powerful algorithms that mainly developed within ML field.
Numerous machine learning algorithms are available.
However, there is no one size fits all algorithm that can be used
in developing a model for complex analysis. Typically, the
algorithms serve specific purposes or specific domain of
interest. Therefore, to build an analytics model, a modeler
follows trial-and error principle to discover the best fitting
algorithm. For instance, a wide number of machine learning
algorithms and statistical methods have been proposed in a
large body of literature such as [
        <xref ref-type="bibr" rid="ref2">2</xref>
        ] [
        <xref ref-type="bibr" rid="ref3">3</xref>
        ] [
        <xref ref-type="bibr" rid="ref4">4</xref>
        ] [
        <xref ref-type="bibr" rid="ref5">5</xref>
        ] [
        <xref ref-type="bibr" rid="ref6">6</xref>
        ] [
        <xref ref-type="bibr" rid="ref7">7</xref>
        ]. However,
the algorithms proposed in these literature produce different
results and different levels of accuracy. Furthermore, it is
commonly seen that the existing machine learning algorithms
very often cannot be used as is, but need to be extended. That
being said, building a complex analytics model is not a
straightforward operation; it needs testing various methods
and algorithms to find best fit in terms of accuracy and
correctness.
      </p>
      <p>We studied a number of existing analytics models for
prognosis. According to our investigation, these models are
built on the top of different statistical methods and machine
learning algorithms. The study shows that the accuracy and
correctness of the results produced by these models vary
greatly. Also, we strongly believe that the accuracy level
achieved by the existing solutions is low and can be improved.</p>
      <p>Our objective is to develop and train an efficient machine
learning model that can estimate the survival time, or the
prognosis, of a patient diagnosed with AML, with high
accuracy, using solely the Gene Expression Levels of a small
group genes. The small number of genes means that the
testing time and costs will be significantly reduced, as the
gene expression levels of such number of genes can be
measured using low-multiplicity technologies. The challenge
will be to identify from thousands of genes the ones that their
expression level can be used effectively to give an accurate
prognosis. And the algorithm that the model will depend on
is Survival Regression.</p>
      <p>The rest of this paper is organized as follows: the second part
is a background on some of the concepts needed for the
understanding of the contribution. The third part is a literary
view on the subject of machine learning in healthcare. The
fourth part is our contribution and the fifth is results. The last
part will be a conclusion.</p>
    </sec>
    <sec id="sec-3">
      <title>II. BACKGROUND</title>
      <sec id="sec-3-1">
        <title>A. Gene Expression Levels</title>
        <p>Gene Expression is the process by which the information
from a gene is used in this synthesis of a functional gene
product such as proteins. Gene expression is
contextdependent and is regulated in several basic ways: by region,
dynamic response to environmental elements, by gene
activity, and in disease states. So it can be said that gene
expression level is one way of mapping his biological
functions, and how well his body is being regulated by his
genes. That is why the amount of gene expression, or the Gene
Expression Level of the genes of a certain individual can give
insight into his biological and thus medical profile.</p>
      </sec>
      <sec id="sec-3-2">
        <title>B. Survival Regression</title>
        <p>Survival analysis is a branch of statistics for analyzing the
expected duration of time until one or more events happen,
such as death in biological organisms and failure in
mechanical system. This is done by studying the relationship
between the Explanatory Variables that lead to that event in a
certain group and the Outcome Variable. For example, in
cancer survival analysis, the event to be observed is the death
of the patient. The time of survival of the patient is “regressed”
against the variables that are under study, and the prognosis of
the patient, or the duration of time before his death, is the
outcome variable.</p>
        <p>
          Survival models can be viewed as consisting of two parts:
the underlying baseline function, often denoted λ0(t),
describing how the risk of event per time unit changes over
time at baseline levels of covariates; and the effect
parameters, describing how the hazard varies in response to
explanatory covariates [
          <xref ref-type="bibr" rid="ref8">8</xref>
          ].
        </p>
        <p>
          One of the branches of survival analysis is the survival
analysis under the Proportional Hazards Conditions. The
proportional hazards condition states that covariates are
multiplicatively related to the hazard. Sir Cox, whom the Cox
Proportional Hazard Model is attributed to, observed that if
the proportional hazards assumption holds, then it is possible
to estimate the effect parameter(s) without any consideration
of the hazard function. This approach to survival data is called
application of the Cox proportional hazards model. Cox also
noted that biological interpretation of the proportional hazards
assumption can be complicated [
          <xref ref-type="bibr" rid="ref8">8</xref>
          ].
        </p>
      </sec>
    </sec>
    <sec id="sec-4">
      <title>III. RELATED WORK</title>
      <p>Several works related to prognosis analysis have been
found in a large bodies of literature. We reported some of the
notable works related to our research.</p>
      <p>
        Sara Haddou Bouazza et al. [
        <xref ref-type="bibr" rid="ref9">9</xref>
        ] discussed a comparison
between five feature selection algorithms to extract the most
significant features from the Gene Microarray Data: F test, T
test, Signal to noise Ratio (S/R), ReliefF and Pearson
ProductMoment Correlation Coefficient (CC). They used datasets of
five cancers: Leukemia, Lung, Lymphoma, Central Nervous
System and Ovarian, and five supervised learning classifiers:
K Nearest Neighbors (KNN), Support Vector Machines
(SVMs), Linear Discriminant Analysis (LDA), Decision Tree
for Classification (DTC), and Naïve Bayes classifier (NB).
They concluded that the selection methods with highest
accuracies across classifiers where: S/R, ReliefF, and CC
respectively.
      </p>
      <p>Feiyu Xion et al. [10] constructed a machine learning
framework called KITML (Kernelized Information-Theoretic
Metric Learning), which depended on the KNN algorithm but
with improved distance metrics to diagnose cancer by finding
similar patient biological profiles while dealing efficiently
with the high dimensionality of microarray gene data. The
performance of the algorithm was compared to others
including KNN with Euclidian Metric, SVM, Random Forest
(RF), and DT. The Macro Average F1 score was used as an
evaluation metric and it showed higher accuracy of the
algorithm, with considerable less execution time.</p>
      <p>Sara Tarak et al. [11] classified cancer types by studying
the Gene Expression Levels in 3 datasets: leukemia, breast,
and colon using the Matlab Bioinformatics and Statistics
Toolboxes. They used the KNN algorithm, with K=3 and built
five classifiers each employing a feature selection method.
The feature selection methods were chosen to avoid
redundancy and noise and are: Backward Elimination
HilbertSchmidt Independence Criterion (BEHSIC), Extreme Value
Distribution (EVD) gene selection, and Singular Value
Decomposition Entropy (SVDEntropy) gene selection. Tuned
their results using Error Estimation, and evaluated them by
using Receiver Operating Characteristic (ROC) and Bayesian
Credible Interval (BRI) methods.</p>
      <p>Kenneth R. Foster et al. [12] published a paper in which
they discussed the great challenges facing the construction of
classifiers in the field of bioinformatics, arguing they are
mostly prone to over-fitting, and generally lack accuracy, and
face a great challenge in the vast number of parameters that
can interfere in the diagnosis process that are not taken into
account. They stated that building classifiers should not be
views simply as an add-on statistical analysis, but a parcel of
the experimentation process, and that the validation of the
classifiers for diagnostic applications should be considered as
part of a much larger process of establishing the clinical
validity of the techniques. The article mainly focuses on
methods to improve the accuracy of SVM classifiers in
bioinformatics unavoidable.</p>
      <sec id="sec-4-1">
        <title>Discussion</title>
        <p>The technologies studied in the above tackle the problem of
prognosis much lesser than diagnosis, as there are many
solutions proposed on cancer diagnosis using different
approach like use of medical imaging and Gene Expression
Levels, however we found little about the prognosis problem.
To the best of our knowledge, there is no solution proposed to
tackle the problem of prognosis through the use of Gene
Expression Levels alone, which have the potential to
overcome the difficulty of producing accurate models, by
eliminating much of the diversity in patients and their data, by
focusing on data from a single, highly reliable source; their
genetic profiles.</p>
        <p>Furthermore, the implementation of the solutions proposed in
literature the is done using classical solutions like Matlab and
other statistical analysis tools rather than using advanced tools
and technologies. This has limitations from a technical
standpoint. Firstly, modification of any algorithm extremely
difficult, very often not possible; the modeler relies on as is
library provided by the development framework. Hence,
improvement of a model is a non-trivial task. Optimization of
performance in terms of computation is entirely impossible.
Sometimes, technologies of these sorts provide some
parameters to optimize performance.</p>
        <p>However, very often it is not an effective approach.
Specifically, for large-scale datasets, the existing solutions
cannot be used meaning that the analysis cannot be performed
these existing solutions. To the best of our knowledge, the
scale of the dataset is critical to produce a comprehensive
result of analysis – which is not possible with existing
solutions.
IV. PROGMOD – A MODEL FOR PROGNOSIS OF AML PATIENTS</p>
        <p>In this section, we present ProgMod for finding the
prognosis of AML patients using solely their gene expression
levels. The process of model construction was sequential and
iterative (shown in Figure 1), in order to find the model with
the highest score. The number of features of different models
varied as the aim was to find an optimal number that is
preferably below 48.</p>
      </sec>
      <sec id="sec-4-2">
        <title>A. ProgMod Development Cycle</title>
        <p>The ProgMod development lifecycle consists of four phases:
Data Preparation, Feature Selection, Model Construction,
Model Evaluation. These tasks briefly described in the
following.</p>
        <p>1) Data Peparation: The dataset we worked with was of
240 AML patients, and is the combination of 2 datasets. 1)
GSE 12417 (78 Patients) 2) TCGA (162 Patients). The
information available about the patinets were three types: 1)
Social Data (Age and Gender) 2) Clinical Informartion Data
(Blast Count, Overall survival time osTime, and overall
survival status osStatus) 3) Genetic Profile Data (Gene
Expression Levels). The first step was to clean the data and
remove the redundant information and extract the ones
needed i.e. osTime, osStatus, and Gene Expression Levels.</p>
        <p>2) Feature Selection: This was done in two different
phases:</p>
      </sec>
      <sec id="sec-4-3">
        <title>a) Preliminary Feature Dimensinonality Reduction:</title>
        <p>The process of applying variance thresholding to remove
features that have low variance regardless of the value of the
outcome variable i.e. the overall survival time. This reduced
the number of featurs from 20000 to 287.</p>
      </sec>
      <sec id="sec-4-4">
        <title>b) Outcome Reliant Feature Selection: Select from the</title>
        <p>reduced variables the ones that best correlate to the outcome
variable. Three features selection methods were used and
tested in order to find the best one, they are: 1) F test 2)
Recursive Feature Elimination 3) Mutual Info Selection.
Sklearn’s feature selection module can be used for feature
selection/dimensionality reduction on sample sets, either to
improve estimators’ accuracy scores or to boost their
performance on very high-dimensional dataset
All the features that had a very low variance in 80% of the
patients were dropped. The result of this process was to
1 http://facweb.cs.depaul.edu/sjost/csc423/documents/f-test-reg.htm
2
https://medium.com/@aneesha/recursive-feature-elimination-with-scikitlearn-3a2cbdf23fb7
reduce the number of features from about 20,000 to 287, these
are the ones that will be used in the next step.</p>
        <p>The second step is outcome reliant feature selection i.e.
selecting the features that best correlate to the outcome
variable, the survival time. First, and since the two dataset
have different methods of measurements of Gene Expression
Levels, they could not be used merged together to perform
feature selection. Instead, the larger dataset, TCGA,
containing 178 patients, was used as a features selection set,
and the second dataset was used as a testing set.</p>
        <p>
          Three feature selection methods were tried, evaluated, and the
one that had the best results was eventually used in the final
model. The three feature selection methods are all modules in
sklearn’s feature selection module. They are the modules:
- f_regresion: the f_test for regression tests whether
any of the independent variables in a multiple linear
regression model is significant using the ratio of
variances obtained from the means squared value. 1
- rfe_regression: recursive feature elimination
recursively removes features, builds a model using
the remaining attributes and calculates model
accuracy. RFE is able to work out the combination
of attributes that contribute to the prediction on the
target variable.2
- Mutual_info_regression: Mutual information is a
measure between two (possibly multi-dimensional)
random variables XX and YY that quantifies the
amount of information obtained about one random
variable, through the other random variable. 3
The pseudo-code for the algorithm used to select the best
model was the following:
for num_features in range (10, 48):
features = select_features
(num_features, Feature_Selection_Set)
model_score = evaluate_model
(features, Test_Set_1, Test_Set_2)
3) Model Constrction: Cox Proportional Hazard
Regression Model is used for developing analytics model. It
is probably the most popular regression technique for
regression analysis of survival data [
          <xref ref-type="bibr" rid="ref8">8</xref>
          ]. The power of the Cox
Model, and what distinguishes it from linear or logistic
regression, is its ability to account for censored data points,
i.e. data points that the time of event remains unknown. In our
example, if the patient that did not die at the end of the
standard five year follow up period, his overall survival status
is labeled as “censored event”. The Cox Model does not
assume the hazard value to be constant, but rather a function
of time. This is due to the fact the hazard in Cox Model is the
same as the incidence rate i.e. the ratio of the subjects who
died over the overall number of subjects ((number of death
events)/(total number of patinets)), thus as time passes and
subjects die, the incidence rate, or the hazard, varies. This
keeps the Model in continuous variation, with the incidence
rate and model predictions variating as data points are
3 https://thuijskens.github.io/2017/10/07/feature-selection/
modified or added to it. If Xi = {X1, X2 … Xn} are the values
of the covariates of subject i, the equation for the Cox Model:
ln  = + + ∑ . (.)
This equation produces a survival function for each patient,
showing the probability of survival over a period of time
(Figure 2).
        </p>
        <p>4) Model Evaluation: As mentioned the Cox Model
predicts a survival function of the probability of the event of
death over time. While this result is ultimately desired, it is
difficult to evaluate the accuracy of the model when the real
value is a number and the predicted value is a function. So an
algorithm was improvised.</p>
        <p>Each model was evaluated by fitting the data with the
features resulting from the features selection process in to the
testing set and scoring the model. The score of each model
was acquired using the module r2_squard_accuracy in
sklearn’s module: metrics. R2 Squared Accuracy is an
algorithm used to predict how well the model will perform on
future unseen data. It takes two matrices, one with the real
values and one with the predicted values.</p>
        <p>The real values used were the actual survival months of
the patients. The predicted values were the values in the
survival function corresponding to constant probability value.
The probability value is irrelevant in this case because the
purpose is comparison between different models. The
predicted survival value for each patient was the value
corresponding to 0.8 probabilty in the survival function.</p>
      </sec>
      <sec id="sec-4-5">
        <title>B. Implementation of ProgMod</title>
        <p>ProgMod was implemented using different Python-based,
open-source libraries available to perform data acquisition
and transformation (Pandas and Numpy), analysis (Scikit
Learn), and visualization (PyPlot).</p>
        <p>For the implementation of the Cox Proportional Hazard
Model, we used the open-source library lifelines, downloaded
from the lifelines website4, and performed some tweaking
and a wrapper around its functions to suit the needs of my
implementation. Lifelines is a library that implements
survival analysis models, including the Cox Proportional
Hazard Model.
https://lifelines.com4</p>
      </sec>
    </sec>
    <sec id="sec-5">
      <title>V. EXPERIMENTS AND RESULTS In this section, we reported results of experiments that we conducted to evaluate ProgMod. I discussed how my model produced results, more specifically prognosis prediction.</title>
      <sec id="sec-5-1">
        <title>A. Model Fitting with Test Data</title>
        <p>Using the test set, the gene expression levels of the 47
genes selected in the previous step were fitted in the Cox
Model alongside the overall survival time and the survival
status. The model was the used to predict the survival
function the patients.</p>
        <p>For the purpose of scoring the model the value from the
survival function of each patient corresponding to the fixed
probabilty 0f 0.8 was taken, and was considered the predicted
survival time for that patient. Then the array of real values
and predicted values were used to score and visualize the
result of the model.</p>
      </sec>
      <sec id="sec-5-2">
        <title>B. Model Scoring</title>
        <p>Two metrics were used to score the model in each test
set, both in sklearn’s module: metrics:
- R2 Squared Accuracy: used to predict how well the
model will perform on future unseen data. Its
formula is: 1 − 5454∑∑:5:5;;44((66..7766&lt;8&lt;..))99
where Yi is the real
value, Y’i is the predicted value, and Y’’i is the mean
value.</p>
      </sec>
      <sec id="sec-5-3">
        <title>Root Mean Squared Error: used to calculate the</title>
        <p>average error per data point. Its formula is:
=?&gt; ∑C?D&gt;( − &lt;)B
and predicted values.</p>
        <p>where yj and y’j are the real
Finally, the lifeline implementation of the Cox Model has its
own score. When data is fitted into the model, it provides a
summery containing a score called the concordance score,
and it show how well the data fit the model.</p>
      </sec>
      <sec id="sec-5-4">
        <title>C. Model Results &amp; Evaluation</title>
        <p>For the test set GSE12417, we plotted the Real and
predicted values to visualize which is shown in Figure 3.</p>
        <p>0.56
72
1.39
56
1.98
07
1.77
41
1.71
29
1.65
38
The interpretation of the summary is the following:
- Statistical Significance: The column marked “z”
gives the Wald statistic value. It corresponds to the
ratio of each regression coefficient to its standard
error (z = coef/se (coef)). The Wald statistic
evaluates, whether the beta (β) coefficient of a given
variable is statistically significantly different from 0.</p>
        <p>The Regression Coefficients: The second feature to
note in the Cox model results is the sign of the
regression coefficients (coef). A positive sign means
that the hazard (risk of death) is higher, and thus the
prognosis worse, for subjects with higher values of
that variable.</p>
        <p>Hazard Ratios: The exponentiated coefficients (exp
(coef) = exp (-0.53) = 0.59), also known as hazard
ratios, give the exact size of covariates.</p>
        <p>Confidence Intervals of the Hazard Ratios. The
summary output also gives upper and lower 95%
confidence intervals for the hazard ratio (exp
(coef)).</p>
        <p>For Example, the genes 5604, 19432, 5521, 7596, and 445
have a p value &lt; 0.001 and are the ones with the most
statistical significance. These means that although we need
all 47 genes to predict an accurate prognosis, these 5 genes
are pretty good indicators of the prognosis of the patient.</p>
      </sec>
    </sec>
    <sec id="sec-6">
      <title>VI. CONCLUSION AND FUTURE WORKS</title>
      <p>In recent years, Bioinformatics is adopting mainstream
technologies of computer science in performing various
complex tasks. Machine learning – a branch of computer
science- is one of the most popular fields of development of
analytical models for performing analysis on critical,
lifesaving subjects such as acute myeloid leukemia (AML).
However, since there is an exhaustive number of algorithms
and methods offered by ML, it is non-trivial task to find the
best one without experimenting them. Furthermore, different
models developed using different approaches produce
different results with different accuracy levels.</p>
      <p>We investigated different models proposed in literature for
prognosis to the patients diagnosed with AML. According to
our study, the results of these models vary which essentially
imply that there is a possibility that the existing models could
be improved in terms of accuracy.</p>
      <p>In this paper, we presented a model to estimate the
prognosis of AML patients using the Cox Proportional Hazard
Model for survival analysis, using their Gene Expression
Levels solely as the explanatory variables, thus overcoming
the issue of high molecular heterogeneity of AML when it
comes to prognosis prediction.</p>
      <p>We have shown that it can estimate the survival time with
r2_squared accuracy of 0.75 with the used dataset. And the
model is valid to perform prediction on future patients. The
number of genes that the model was constructed to work with
is 47, a small number that with modern technologies can be
tested with relatively small costs and time.</p>
      <p>An extension of this work is lined up. That is, this
approach can be extended to all sorts of cancer. However, the
model has to be adjusted and generalized to select the
significant genes, and perform the prognosis prediction of any
cancer, based on the Gene Expression Levels of these selected
genes.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <mixed-citation>
          [1]
          <string-name>
            <given-names>H.</given-names>
            <surname>Döhner</surname>
          </string-name>
          ,
          <string-name>
            <given-names>J. D.</given-names>
            <surname>Weisdorf</surname>
          </string-name>
          and
          <string-name>
            <given-names>C. D.</given-names>
            <surname>Bloom</surname>
          </string-name>
          ,
          <article-title>"Acute Myeloid Leukemia,"</article-title>
          <source>The New England Journal of Medicine</source>
          ,
          <year>2015</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation>
          [2]
          <string-name>
            <surname>Golub</surname>
            ,
            <given-names>T. R.</given-names>
          </string-name>
          et al.,
          <article-title>"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," science</article-title>
          ,
          <volume>286</volume>
          (
          <issue>5439</issue>
          ),
          <fpage>531</fpage>
          -
          <lpage>537</lpage>
          .,
          <year>1999</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation>
          [3]
          <string-name>
            <given-names>M. L.</given-names>
            <surname>Gulley</surname>
          </string-name>
          ,
          <string-name>
            <given-names>T. C.</given-names>
            <surname>Shea</surname>
          </string-name>
          and
          <string-name>
            <given-names>Y.</given-names>
            <surname>Fedoriw</surname>
          </string-name>
          ,
          <article-title>"Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia,"</article-title>
          <source>The Journal of Molecular Diagnostics</source>
          ,
          <year>2010</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation>
          [4]
          <string-name>
            <given-names>Den</given-names>
            <surname>Boer</surname>
          </string-name>
          et al.,
          <article-title>"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study,"</article-title>
          <source>The Lancet Oncology</source>
          ,
          <year>2009</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation>
          [5]
          <string-name>
            <given-names>S.</given-names>
            <surname>Mi</surname>
          </string-name>
          ,
          <string-name>
            <given-names>J.</given-names>
            <surname>Lu</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M.</given-names>
            <surname>Sun</surname>
          </string-name>
          ,
          <string-name>
            <given-names>Z.</given-names>
            <surname>Li</surname>
          </string-name>
          ,
          <string-name>
            <given-names>H.</given-names>
            <surname>Zhang</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M. B.</given-names>
            <surname>Neilly</surname>
          </string-name>
          and
          <string-name>
            <given-names>S. K.</given-names>
            <surname>Bohlander</surname>
          </string-name>
          ,
          <article-title>"MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia,"</article-title>
          <source>Proceedings of the National Academy of Sciences</source>
          ,
          <year>2007</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation>
          [6]
          <string-name>
            <given-names>Ali</given-names>
            <surname>Nehme</surname>
          </string-name>
          et al.,
          <article-title>"Atlas of tissue renin-angiotensinaldosterone system in human: A transcriptomic metaanalysis,"</article-title>
          <source>Scientific reports</source>
          ,
          <year>2015</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation>
          [7]
          <string-name>
            <given-names>K.</given-names>
            <surname>Wheatly</surname>
          </string-name>
          et al.,
          <article-title>"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials,"</article-title>
          <source>British journal of haematology</source>
          ,
          <year>2009</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation>
          [8]
          <string-name>
            <surname>P. C. van Dijk</surname>
          </string-name>
          ,
          <string-name>
            <given-names>K. J.</given-names>
            <surname>Jager</surname>
          </string-name>
          ,
          <string-name>
            <given-names>A. H.</given-names>
            <surname>Zwinderman</surname>
          </string-name>
          ,
          <string-name>
            <given-names>C.</given-names>
            <surname>Zoccali</surname>
          </string-name>
          and
          <string-name>
            <given-names>F. W.</given-names>
            <surname>Dekker</surname>
          </string-name>
          ,
          <article-title>"The analysis of survival data in nephrology: basic concepts and methods of Cox regression," abc of epidemiology</article-title>
          ,
          <year>2008</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation>
          [9]
          <string-name>
            <given-names>S. H.</given-names>
            <surname>Bouazza</surname>
          </string-name>
          ,
          <string-name>
            <given-names>K.</given-names>
            <surname>Auhmani</surname>
          </string-name>
          ,
          <string-name>
            <given-names>A.</given-names>
            <surname>Zeroual</surname>
          </string-name>
          and
          <string-name>
            <given-names>N.</given-names>
            <surname>Hamdi</surname>
          </string-name>
          ,
          <article-title>"Selecting Significant Marker Genes From Microarray Data by Filter Approach for Cancer Diagnosis,"</article-title>
          <source>Procedia Computer Science</source>
          <volume>127</volume>
          ,
          <year>2018</year>
          .
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>